Stick With Gamida Cell Ltd (GMDA). The Bull Are Alive And Well

Currently, there are 144.44M common shares owned by the public and among those 116.93M shares have been available to trade.

The company’s stock has a 5-day price change of -91.04% and -88.78% over the past three months. GMDA shares are trading -91.25% year to date (YTD), with the 12-month market performance down to -95.27% lower. It has a 12-month low price of $0.05 and touched a high of $2.51 over the same period. GMDA has an average intraday trading volume of 5.08 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -89.38%, -89.77%, and -95.59% respectively.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Institutional ownership of Gamida Cell Ltd (NASDAQ: GMDA) shares accounts for 31.65% of the company’s 144.44M shares outstanding.

It has a market capitalization of $4.79M and a beta (3y monthly) value of 0.95. The earnings-per-share (ttm) stands at -$0.65. Price movements for the stock have been influenced by the stock’s volatility, which stands at 27.05% over the week and 13.43% over the month.

Analysts forecast that Gamida Cell Ltd (GMDA) will achieve an EPS of -$0.13 for the current quarter, -$0.14 for the next quarter and $0 for 2025. The lowest estimate earnings-per-share for the quarter is -$0.14 while analysts give the company a high EPS estimate of -$0.13. Comparatively, EPS for the current quarter was -$0.27 a year ago.

Looking at the support for the GMDA, a number of firms have released research notes about the stock. Alliance Global Partners stated their Buy rating for the stock in a research note on November 01, 2021, with the firm’s price target at $11. Piper Sandler was of a view on May 26, 2020 that the stock is Overweight, while H.C. Wainwright gave the stock Buy rating on April 27, 2020, issuing a price target of $15. Needham on their part issued Buy rating on November 26, 2018.

Most Popular

Related Posts